XML 115 R66.htm IDEA: XBRL DOCUMENT v3.21.1

Revenue from Contracts with Customers - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2020 EUR (€) Country Customer	Dec. 31, 2019 EUR (€) Customer	Dec. 31, 2018 EUR (€) Customer
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Number of customers | Customer	2	1	2
Revenues from contracts with customers	€ 482,325	€ 108,589	€ 127,575
Milestone payment recognized as revenue	51,800
Revenues derived from deferred upfront payments	52,100
Remaining upfront fees contract liabilities	131,800	187,600
Advance payment received for future COVID 19 vaccine sale	235,800
Research & Development
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	178,849	84,428	101,837
Revenue from collaboration	3,500
Non refundable upfront cash payment	66,300
Commercial
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	€ 303,476	24,161	25,738
Conditional marketing authorization countries | Country	65
Other Sales Transactions
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	€ 33,000	24,200	25,700
Advance payments received on other sales	€ 3,900	3,100
Minimum
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Trade receivable maturity period	20 days
Maximum
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Trade receivable maturity period	30 days
Pfizer Inc.
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	€ 371,500
Pfizer Inc. | Research & Development
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	€ 121,597	14,348	7,173
Pfizer Inc. | Minimum
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Percentage of revenue	10.00%
Genentech Inc
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	€ 49,200	64,000	49,500
Genentech Inc | Research & Development
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	€ 49,195	€ 64,026	€ 49,536
Genentech Inc | Minimum
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Percentage of revenue	10.00%	10.00%	10.00%
Sanofi S.A.
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers			€ 41,700
Sanofi S.A. | Cellscript Sublicense
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers			€ 33,200
Percentage of reimbursement of sublicense costs			50.00%
Sublicense agreement date			Dec. 22, 2018
Sanofi S.A. | Minimum
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Percentage of revenue			10.00%
Fosun Pharma | Research & Development
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Non refundable upfront cash payment	€ 900
Milestone payment recognized as revenue	4,200
Revenues from Selling Drug Product Batches to Pfizer's Manufacturing Site | Commercial
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	61,500
BioNTech | Commercial | Germany
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	20,600
BioNTech | Bill and Hold Transaction
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers		€ 1,100
Revenue from Share of Collaboration Partner's Gross Profit | Commercial
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Revenues from contracts with customers	€ 188,500

X

- Definition

Advance payment received for future COVID 19 vaccine sale.

+ References

No definition available.

+ Details

Name:	bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Conditional marketing authorization countries.

+ References

No definition available.

+ Details

Name:	bntx_ConditionalMarketingAuthorizationCountries
Namespace Prefix:	bntx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Milestone payment recognized as revenue.

+ References

No definition available.

+ Details

Name:	bntx_MilestonePaymentRecognizedAsRevenue
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non refundable upfront cash payment.

+ References

No definition available.

+ Details

Name:	bntx_NonRefundableUpfrontCashPayment
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number of customers.

+ References

No definition available.

+ Details

Name:	bntx_NumberOfCustomers
Namespace Prefix:	bntx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of reimbursement of sublicense costs.

+ References

No definition available.

+ Details

Name:	bntx_PercentageOfReimbursementOfSublicenseCosts
Namespace Prefix:	bntx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Remaining upfront fees contract liabilities.

+ References

No definition available.

+ Details

Name:	bntx_RemainingUpfrontFeesContractLiabilities
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Revenue from collaboration.

+ References

No definition available.

+ Details

Name:	bntx_RevenueFromCollaboration
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenues derived from deferred upfront payments.

+ References

No definition available.

+ Details

Name:	bntx_RevenuesDerivedFromDeferredUpfrontPayments
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Sublicense agreement date.

+ References

No definition available.

+ Details

Name:	bntx_SublicenseAgreementDate
Namespace Prefix:	bntx_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Trade receivable maturity period.

+ References

No definition available.

+ Details

Name:	bntx_TradeReceivableMaturityPeriod
Namespace Prefix:	bntx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of current payments received for goods or services to be provided in the future. [Refer: Advances received]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_55&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_CurrentAdvances
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The percentage of the entity's revenue. [Refer: Revenue]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_PercentageOfEntitysRevenue
Namespace Prefix:	ifrs-full_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2020-01-01
-Paragraph 113
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2020-01-01
-Paragraph 114
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_114&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=bntx_OtherSalesTransactionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=bntx_SanofiSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=bntx_CellscriptSublicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=bntx_FosunPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=bntx_BioNTechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_DE
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=bntx_BillAndHoldTransactionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: